Darinaparsin is under clinical development by Solasia Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Darinaparsin’s likelihood of approval (LoA) and phase transition for Peripheral T-Cell Lymphomas (PTCL) took place on 29 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Darinaparsin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Darinaparsin (Darvias) is an organoarsenic derivative. It is formulated as powder for solution for intravenous drip route of administration. Darvias is indicated for relapsed or refractory peripheral t-cell lymphoma in adults.
Darinaparsin (Zinapar, ZIO-101) is under development for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell Lymphoma (AITL), and anaplastic large cell lymphoma (ALCL). The drug candidate is administered through injection, intravenously and orally. Darinaparsin is organic arsenic derivative. It was also under development for treatment of solid tumors, relapsed/refractory acute leukemia, chronic myeloproliferative disease, chronic lymphoproliferative disease, lymphoma, myelodysplasia, Non-Hodgkin lymphoma and Hodgkin lymphoma, refractory/relapsed multiple myeloma, pancreatic cancer, prostate cancer, adult T-cell leukemia, acute myeloid leukemia (AML), and hepatocellular carcinoma.
Solasia Pharma overview
Solasia Pharma, formerly JapanBridge, is a pharmaceutical company that provides patient access to oncology therapies. The company develops and commercializes oncology therapies and cancer supportive care products. It develops SP-01, a transdermal delivery system, which delivers the anti-emetic and granisetron in the patient’s bloodstream without the need for injections and swallowing pills; and SP-02, a mitochondrial-targeted agent used for the treatment of various hematologic and solid cancers. Solasia Pharma offers SP-03, an oral liquid for the treatment of pain associated with oral mucositis and SP-04. The company markets its products to Japan, China and Asian countries. Solasia Pharma is headquartered in Tokyo, Japan
Quick View Darinaparsin LOA Data
|Highest Development Stage|